Collectively, these data support the notion that enhanced ALOX15B expression in macrophages contribute to increased CCL17 production in an SREBP-2-dependent manner, and suggest that alternative therapies to reduce CCL17 levels and subsequent T cell migration by targeting the 15-LOX enzymes may offer therapeutic potential for treating chronic airway diseases such as asthma. Here, ALOX15B is linked to asthma.